Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * BAFFI ROBERT	2. Date of Event Requiring Statement (MM/DD/YYYY) 7/15/2021	3. Issuer Name and Ticker or Trading Symbol Mosaic ImmunoEngineering Inc. [CPMV]
(Last)        (First)        (Middle) 1537 SOUTH NOVATO BLVD, #5	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                          _____ 10% Owner _____ Officer (give title below)        _____ Other (specify below)
(Street) NOVATO, CA 94947       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	7/15/2022 (2)	(1)	Common Stock	51497	(1)	D
Convertible Note (3)	(3)(4)	(3)	see footnote (3)(4)(5)	$100000	(3)(4)(5)	D

Explanation of Responses:
(1)	Each Restricted Stock Unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock, for no consideration.
(2)	RSU's granted under the 2020 Mosaic ImmunoEngineering Omnibus Incentive Plan for non-employee Board compensation. RSUs will vest 100% on July 15, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date.
(3)	The Convertible Notes were issued on May 7, 2021 in exchange of $100,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 4 and 5) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 4 and 5).
(4)	Upon a Qualified Financing or Smaller Financing (see footnote 5), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $2.377.
(5)	A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes).

Remarks: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BAFFI ROBERT 1537 SOUTH NOVATO BLVD, #5 NOVATO, CA 94947	X

Signatures
/s/ Paul Lytle, as attorney-in-fact for Robert A. Baffi, Ph.D.		7/16/2021
**Signature of Reporting Person		Date